Johns Hopkins ABX Guide
Voriconazole
Voriconazole is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Voriconazole is FDA approved for the following indications in adults and pediatrics ≥ 2 years of age:
- Invasive aspergillosis
- Serious infections caused by Scedosporium apiospermum (Pseudallescheria boydii) and Fusarium spp. (including F. solani) in patients intolerant of, or refractory to, other therapies.
- Esophageal candidiasis
- Candidemia in non-neutropenic patients and other deep tissue Candida infections
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Prophylaxis of invasive aspergillosis and disseminated candidiasis in severely immunocompromised hosts
- Based on in-vitro data and limited clinical experience, voriconazole may be effective for infections due to certain dematiaceous fungi (C. immitis)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Voriconazole is FDA approved for the following indications in adults and pediatrics ≥ 2 years of age:
- Invasive aspergillosis
- Serious infections caused by Scedosporium apiospermum (Pseudallescheria boydii) and Fusarium spp. (including F. solani) in patients intolerant of, or refractory to, other therapies.
- Esophageal candidiasis
- Candidemia in non-neutropenic patients and other deep tissue Candida infections
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Prophylaxis of invasive aspergillosis and disseminated candidiasis in severely immunocompromised hosts
- Based on in-vitro data and limited clinical experience, voriconazole may be effective for infections due to certain dematiaceous fungi (C. immitis)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 8, 2022
Citation
Avdic, Edina. "Voriconazole." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540588/all/Voriconazole.
Avdic E. Voriconazole. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540588/all/Voriconazole. Accessed July 5, 2022.
Avdic, E. (2022). Voriconazole. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540588/all/Voriconazole
Avdic E. Voriconazole [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2022 July 05]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540588/all/Voriconazole.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Voriconazole
ID - 540588
A1 - Avdic,Edina,Pharm.D.
Y1 - 2022/01/08/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540588/all/Voriconazole
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
